GK Q&A, page-57

Thank you for your courteous response, RBx - and credit to my friend, Tyler80 for taking the initiative to provide the Q&A's to NRT share holder enquiries.

As Tyler is already aware, I don't necessarily agree with all the positive points being highlighted by fellow holders on this forum in favor of NRT, however it should also be noted that whenever the contrarian view is met with courtesy as opposed to personal insult, everyone on HC benefits.

Personally, I still believe that seeking a licensing partner to progress pivotal trials in the field of new cancer therapeutics is absolutely essential to the success of any small biotech company today, more so than ever before. Importantly, it also provides a very significant endorsement for the odd one or two stand-outs, among the 1000's of new cancer cure promoters we have to endure every year.

Let history be our guide, and don't neglect the new paradigm shift and current adoption of new business models which are already starting to obsolete what little glimmer of hope was left for the small player.

Cancer is very big business - investors should not ignore this!